GSK receives offer for thrombosis brands

18th Jun 2013 12:16

FTSE 100-listed global pharmaceuticals company GlaxoSmithKline(GSK) has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare. The group said that a period of exclusivity had been agreed with Aspen and GSK would respond to the offer, subject to consultation with employees and the relevant works councils. The group said that the financial terms were confidential at this time but that the offer included the transfer of the Arixtra and Fraxiparine brands, excluding China, India and Pakistan to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline.GSK's share price was down 0.47% to 1,678p at 12:27 on Tuesday.MF